Title: Plasma P-tau231: A Promising Biomarker for Detecting Alzheimer's Disease Pathology

Abstract:

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and tau pathology in the brain. The early detection of AD pathology is crucial for timely intervention and potential disease modification. Recent advances in biomarker research have focused on identifying reliable and accessible markers of AD pathology. In this context, a novel plasma p-tau231 assay has emerged as a promising tool for detecting incipient AD pathology. This study aimed to evaluate the diagnostic accuracy of plasma p-tau231 as a biomarker for AD.

The plasma p-tau231 assay measures the phosphorylation of tau protein at threonine 231 (T231), a site specifically associated with tau pathology in AD. Elevated levels of plasma p-tau231 have been observed in individuals with AD, suggesting its potential as a biomarker for detecting tau pathology. The assay's diagnostic performance was evaluated in a cohort of individuals with varying degrees of AD pathology, as determined by Aβ positron emission tomography (PET) and tau PET imaging.

The results demonstrated that plasma p-tau231 levels were significantly elevated in individuals with Aβ-positive status and tau pathology, indicating a strong association between plasma p-tau231 and AD pathology. Receiver operating characteristic (ROC) curve analysis revealed that plasma p-tau231 accurately discriminated between Aβ-positive and Aβ-negative individuals, with an area under the curve (AUC) of 0.92. Furthermore, plasma p-tau231 was able to detect tau pathology in individuals with early-stage AD, suggesting its potential for early diagnosis.

The findings of this study support the use of plasma p-tau231 as a promising biomarker for detecting incipient AD pathology. The high diagnostic accuracy of the assay, combined with its minimally invasive nature, makes it an attractive tool for clinical practice and research settings. The ability to detect AD pathology at an early stage has significant implications for disease diagnosis, monitoring, and treatment. As the field of AD research continues to evolve, the development of reliable biomarkers such as plasma p-tau231 will be crucial for the evaluation of disease-modifying therapies and the implementation of precision medicine approaches.

In conclusion, this study demonstrates the potential of plasma p-tau231 as a biomarker for detecting Alzheimer's disease pathology, particularly in its early stages. Further research is warranted to validate these findings and explore the utility of plasma p-tau231 in diverse clinical populations.